Compass Reconciled Depreciation from 2010 to 2025

CMPX Stock  USD 3.02  0.20  6.21%   
Compass Therapeutics Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation will likely drop to about 1.6 M in 2025. During the period from 2010 to 2025, Compass Therapeutics Reconciled Depreciation regression line of annual values had r-squared of  0.08 and arithmetic mean of  1,907,108. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2019-09-30
Previous Quarter
466 K
Current Value
465 K
Quarterly Volatility
240.9 K
 
Covid
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9.5 M or Interest Income of 9.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.26. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Compass Therapeutics Correlation against competitors.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Latest Compass Therapeutics' Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of Compass Therapeutics over the last few years. It is Compass Therapeutics' Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

Compass Reconciled Depreciation Regression Statistics

Arithmetic Mean1,907,108
Geometric Mean1,898,773
Coefficient Of Variation9.79
Mean Deviation104,351
Median1,921,000
Standard Deviation186,684
Sample Variance34.9B
Range822.3K
R-Value(0.28)
Mean Square Error34.4B
R-Squared0.08
Significance0.29
Slope(11,044)
Total Sum of Squares522.8B

Compass Reconciled Depreciation History

20251.6 M
20241.7 M
20231.9 M
20221.9 M
20211.6 M
20202.4 M
20192.1 M

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation1.7 M1.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.